Abstract:Alopecia areata (AA) is a chronic, multifactorial, polygenic, and heterogeneous disorder affecting growing hair follicles in susceptible individuals, which results in a non-scarring and reversible hair loss with a highly unpredictable course. Despite very considerable research effort, the nature of the precipitating factor(s) responsible for initiating AA in any given hair follicle remains unclear, due largely to significant gaps in our knowledge of the precise sequence of the etiopathogenic events in this dermatosis. However, disease-related changes in the immune-competence of the lower growing hair follicle, together with an active immune response (humoral and cellular) to hair follicle-associated antigens, are key associated phenomena. Confirmation of the hair follicle antigen(s) implicated in AA disease onset has remained stubbornly elusive. While it may be considered somewhat philosophical by some, it is also unclear whether immune-mediated hair loss in AA results from a) an ectopic (i.e., in an abnormal location) immune response to native (unmodified) self-antigens expressed by the healthy hair follicle, b) a normal immune response against modified self-antigens (or neoantigens), or c) a normal immune response against self-antigens (modified/non-modified) that were not previously visible to the immune system (because they were conformationally-hidden or sequestered) but become exposed and presentable in an MHC-I/-II molecule-restricted manner. While some candidate hair follicle antigen target(s) in AA are beginning to emerge, with a potential role for trichohyalin, it is not yet clear whether this represents the initial and immunodominant antigenic focus in AA or is simply one of an expanding repertoire of exposed hair follicle tissue damage-associated antigens that are secondary to the disease. Confirmation of autoantigen identity is essential for our understanding of AA etiopathogenesis, and consequently for developing a more informed therapeutic strategy. Major strides have been made in autoantigen discovery in other autoimmune conditions. In particular, some of these conditions may provide insights into how post-translational modifications (e.g., citrullination, deamidation, etc.) of hair follicle-restricted proteins may increase their antigenicity and so help drive the anti-hair follicle immune attack in AA.

Refractory alopecia areata with single hairs imitating frontal fibrosing alopecia: a prospective observational study

Linear Alopecia Areata.

JAK Inhibitors for the Treatment of Alopecia Areata

Frontal fibrosing alopecia: reflections and hypotheses on aetiology and pathogenesis

A Retrospective Study of Frontal Fibrosing Alopecia from North-East India

Autoantigen Discovery in the Hair Loss Disorder, Alopecia Areata: Implication of Post-Translational Modifications

Stratification of alopecia areata reveals involvement of CD4 T cell populations and altered faecal microbiota

Frontal Fibrosing Alopecia: An Update on Pathogenesis, Diagnosis, and Treatment

Identification of SLC40A1, LCN2, CREB5, and SLC7A11 as ferroptosis-related biomarkers in alopecia areata through machine learning

Transcriptome analysis of frontal fibrosis alopecia revealed involvement of immune cells and ferroptosis

Enhanced Insights into Frontal Fibrosing Alopecia: Advancements in Pathogenesis Understanding and Management Strategies

Clinicopathological Characteristics of Fibrosing Alopecia in a Pattern Distribution: a Single-Center, Retrospective Study

Frontal fibrosing alopecia: A review of disease pathogenesis

Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management

Familial frontal fibrosing alopecia: A cross‐sectional study of 20 cases from nine families

The Clinical Features of Frontal Fibrosing Alopecia: A Review of 7 Cases

Distinctive age distribution and hair loss pattern putatively highlighting uniqueness of Japanese cases of fibrosing alopecia in a pattern distribution

Extra-follicular cutaneous manifestations of frontal fibrosing alopecia

The value of immunohistochemical expression of SOX9 and CD34 in alopecia areata

Recent advances in the genetics of alopecia areata

Non-scarring patchy alopecia in patients with systemic lupus erythematosus differs from that of alopecia areata